A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib
Authors
Keywords
-
Journal
United European Gastroenterology Journal
Volume 3, Issue 5, Pages 453-461
Publisher
SAGE Publications
Online
2015-04-29
DOI
10.1177/2050640615583587
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
- (2014) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
- (2014) Yingmiao Liu et al. INVESTIGATIONAL NEW DRUGS
- Systemic therapy in HCC: Lessons from brivanib
- (2014) David Bolos et al. JOURNAL OF HEPATOLOGY
- Endoglin for Targeted Cancer Treatment
- (2014) Lee S. Rosen et al. Current Oncology Reports
- Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
- (2014) Yingmiao Liu et al. Cancer Medicine
- Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
- (2013) A. B. Nixon et al. CLINICAL CANCER RESEARCH
- New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
- (2013) R. Lencioni CLINICAL CANCER RESEARCH
- Everolimus is a potent inhibitor of activated hepatic stellate cell functionsin vitroandin vivo, while demonstrating anti-angiogenic activities
- (2013) Anne-Christine Piguet et al. CLINICAL SCIENCE
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database
- (2013) Tobias Eggert et al. United European Gastroenterology Journal
- Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies
- (2012) Austin Duffy et al. HEPATOLOGY
- Endoglin Requirement for BMP9 Signaling in Endothelial Cells Reveals New Mechanism of Action for Selective Anti-Endoglin Antibodies
- (2012) Olivier Nolan-Stevaux et al. PLoS One
- Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives
- (2012) Andrew X. Zhu SEMINARS IN ONCOLOGY
- A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
- (2010) Fumihiko Kanai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Matrix Metalloproteinase-14 (MT1-MMP)-Mediated Endoglin Shedding Inhibits Tumor Angiogenesis
- (2010) L. J. A. C. Hawinkels et al. CANCER RESEARCH
- Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)
- (2010) D. Koeberle et al. ONCOLOGIST
- Developing better treatments in hepatocellular carcinoma
- (2010) Austin Duffy et al. Expert Review of Gastroenterology & Hepatology
- Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
- (2009) N Murukesh et al. BRITISH JOURNAL OF CANCER
- Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
- (2009) A. Rapisarda et al. MOLECULAR CANCER THERAPEUTICS
- Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy
- (2008) N. A. Dallas et al. CLINICAL CANCER RESEARCH
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started